Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.
Claim company profile to post jobs directly on this page and this website.